Sino Biopharmaceutical Limited (01177.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.53

From 52W high−37.27%

Volume96.51M

Market capHKD 98.47B

P/E (TTM)35.2x

P/S (TTM)2.5x

Div yield2.19%

Key dataSep 18, 2026

Open

HKD 5.53

From 52W high

−37.27%

Volume

96.51M

Market cap

HKD 98.47B

ValuationView details →

P/E (Fwd)

12.8x

EV/EBITDA

8.4x

P/E (TTM)

35.2x

RSI (14)

52.6

MomentumView details →

1D Return

−0.45%

YTD Return

−11.49%

ValuationView details →

P/E (Fwd)

12.8x

P/E (TTM)

35.2x

EV/EBITDA

8.4x

EV/Sales

2.6x

P/S (TTM)

2.5x

P/B (TTM)

2.6x

ProfitabilityView details →

Gross Margin

82.43%

Net Margin

7.09%

EBITDA Margin

30.89%

ROE (TTM)

7.34%

ROA (TTM)

2.87%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

+10.26%

EPS YoY

−38.48%

FCF YoY

+78.69%

Revenue CAGR 3Y

+6.95%

EPS CAGR 3Y

+5.73%

EBITDA YoY

+70.30%

MomentumView details →

1D Return

−0.45%

YTD Return

−11.49%

1Y Return

−35.34%

RSI (14)

52.6

vs 50D SMA

+4.28%

vs 200D SMA

−4.68%

Capital & dividendView details →

Debt/Equity

0.53x

Current Ratio

1.63x

Quick Ratio

1.56x

Div Yield

2.19%

Div Rate

HKD 0.12

Div Growth 1Y

+33.33%

EarningsView details →

EPS (Actual)

HKD 0.22

EPS Surprise

58.56%

Beats (12Q)

1/12

Next Q EPS Est

HKD 0.13

Avg Surprise (4Q)

58.56%

Rev Surprise

0.68%

Financials snapshotView financials →

Revenue (TTM)

33.70B

Net Income (TTM)

2.39B

Op. CF (TTM)

6.13B

Next earningsApr 1, 2027 →

Latest newsMore news →

China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.3d ago

Sino Biopharmaceutical's management reiterated its full-year guidance for double-digit year-on-year revenue growth, driven by licensing income and innovative drug sales.3d ago

Similar companies

MedPacto, Inc.235980.KQ Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ iNtRON Biotechnology, Inc.048530.KQ CG Invites Co., Ltd.083790.KQ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.06990.HK ORIENT BIO Inc.002630.KS Find similar companies →

Latest newsMore news →

China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.3d ago Sino Biopharmaceutical's management reiterated its full-year guidance for double-digit year-on-year revenue growth, driven by licensing income and innovative drug sales.3d ago China Biologic Products (01177.HK) shares rose 3.62% to HK$5.585 in morning trading on August 21, 2026, following its earnings release.31d ago